Chemical compound
Fosnetupitant is a medication used for the treatment of chemotherapy-induced nausea and vomiting. It is a prodrug of netupitant.[1] It is used in combination with palonosetron hydrochloride and formulated as the salt fosnetupitant chloride hydrochloride for intravenous use.[2]
In 2018, the US Food and Drug Administration approved the intravenous formulation of a fixed dose combination of fosnetupitant and palonosetron.[3][4] The combination is also approved for medical use in the European Union,[5] and in Canada.[6]
References